Ceribell Secures FDA 510(k) Clearance for First Continuous EEG-Based Delirium Monitoring System
Ceribell has received FDA 510(k) clearance for its delirium monitoring solution, making it the first device of its kind to be cleared for continuous screening and monitoring of delirium using EEG data. This approval extends the capabilities of the Ceribell System, an AI-driven platform already utilised for seizure detection, enabling it to support a wider range of critically ill patients who are at risk of both seizures and delirium.
The company developed the technology to address limitations of current delirium assessments, which rely on intermittent bedside evaluations that can vary between providers. Juliana Barr, MD, professor emerita of anesthesiology at Stanford University School of Medicine, said delirium remains a significant challenge in critical care. “Current detection methods rely on intermittent, labor-intensive bedside assessments that are subject to human variability. Ceribell offers a reliable continuous monitoring solution that has the potential to improve delirium detection rates and management,” she said.
Ceribell’s algorithm analyzes EEG segments and alerts clinicians when patterns suggestive of delirium appear, enabling continuous bedside monitoring alongside seizure and electrographic status epilepticus detection. The technology was validated through prospective studies involving 225 adult ICU patients, confirming consistent performance in real-world critical care environments. The company’s work follows its 2022 Breakthrough Device Designation and has prompted a New Technology Add-on Payment application to the Centers for Medicare and Medicaid Services.
Delirium affects an estimated 31 percent of ICU patients and up to 80 percent of those requiring mechanical ventilation. It is associated with longer hospital stays, higher costs, increased mortality, and a significantly elevated risk of long-term cognitive decline. Hypoactive delirium often goes unnoticed due to a subtle clinical presentation, underscoring the need for objective, continuous monitoring. Research also points to a clinical link between seizures and delirium, with studies reporting peri-ictal delirium or epileptiform discharges in a substantial portion of affected patients.
Jane Chao, PhD, co-founder and CEO of Ceribell, said delirium remains “under recognized and under treated in critically ill patients for far too long,” and emphasized the impact of the new clearance. She added that the company aims to advance EEG as “a new vital sign for better brain care” as it finalizes its commercial strategy for the expanded platform.
